Hepatitis C: all 2,356 studies

Page 6 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.

• Boceprevir and Ucalm (St John&Apos;s Wort)CompletedNCT01663922Phase 1Results posted
• A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis CCompletedNCT01659567Results posted
• Dose Ranging of GSK2336805 in Combination TherapyCompletedNCT01648140Phase 2Results posted
• Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV InfectionCompletedNCT01641640Phase 3Results posted
• Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/NaloxoneCompletedNCT01637922Phase 1Results posted
• Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected PatientsCompletedNCT01636778Phase 2Results posted
• Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCompletedNCT01628692Phase 2Results posted
• Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV StudiesCompletedNCT01625338Phase 3Results posted
• A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination StudyCompletedNCT01609933Phase 2Results posted
• Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)TerminatedNCT01606800Phase 4Results posted
• Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)CompletedNCT01604850Phase 3Results posted
• An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis CCompletedNCT01604291Results posted
• Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedNCT01598090Phase 3Results posted
• Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant RecipientsTerminatedNCT01592006Phase 4Results posted
• A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01591460Phase 4Results posted
• Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed TreatmentCompletedNCT01585584Phase 3Results posted
• A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)CompletedNCT01585324Phase 4Results posted
• Herpes Simplex Type 1 Suppression in Hepatitis CCompletedNCT01580995Phase 2Results posted
• Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal ImpairmentCompletedNCT01580306Phase 1Results posted
• Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination TrialCompletedNCT01579474Phase 3Results posted
• Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal CirculationCompletedNCT01579162Not applicableResults posted
• Drug-drug Interaction of BI 201335 and MicrogynonCompletedNCT01570244Phase 1Results posted
• Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedNCT01565889Phase 1/2Results posted
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected SubjectsCompletedNCT01563536Phase 2Results posted
• Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-TransplantCompletedNCT01559844Phase 2Results posted
• Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)CompletedNCT01544920Phase 3Results posted
• Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)CompletedNCT01544582Results posted
• Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take InterferonCompletedNCT01542788Phase 3Results posted
• A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)CompletedNCT01537900Phase 1Results posted
• Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)CompletedNCT01532973Phase 1Results posted
• Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis CTerminatedNCT01532908Phase 2Results posted
• This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedNCT01528735Phase 2Results posted
• Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor MutationsCompletedNCT01517529Results posted
• An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1CompletedNCT01508130Results posted
• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedNCT01500772Phase 3Results posted
• The Boceprevir and Sildenafil Pharmacokinetics StudyCompletedNCT01499498Phase 1Results posted
• Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01498068Phase 3Results posted
• Phase 3 Study of Sofosbuvir and RibavirinCompletedNCT01497366Phase 3Results posted
• Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01492426Phase 3Results posted
• TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin TherapyCompletedNCT01485991Phase 3Results posted
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV InfectionCompletedNCT01482767Phase 3Results posted
• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1CompletedNCT01479868Phase 3Results posted
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV VirusCompletedNCT01471574Phase 3Results posted
• Armodafinil for Patients Starting Hepatitis C Virus TreatmentTerminatedNCT01470651Phase 4Results posted
• An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTerminatedNCT01467505Phase 2Results posted
• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
• A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)TerminatedNCT01467479Phase 3Results posted
• A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive PatientsCompletedNCT01466790Phase 2Results posted
• ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected PatientsCompletedNCT01464827Phase 2Results posted
• Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
• A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)CompletedNCT01458535Phase 2Results posted
• Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)CompletedNCT01453075Phase 1Results posted
• Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis CCompletedNCT01448044Phase 3Results posted
• An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis CCompletedNCT01447446Results posted
• A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01447420Phase 4Results posted
• Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedNCT01446250Phase 3Results posted
• GS-7977 With Ribavirin for Hepatitis C (SPARE)CompletedNCT01441180Phase 1/2Results posted
• Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)TerminatedNCT01440595Phase 2Results posted
• Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsCompletedNCT01439373Phase 2Results posted
• Staged Phase I/II Hepatitis C Prophylactic VaccineCompletedNCT01436357Phase 1/2Results posted
• A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01429792Phase 4Results posted
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedNCT01428063Phase 2Results posted
• Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative VolunteersCompletedNCT01427504Not applicableResults posted
• The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)CompletedNCT01425203Phase 3Results posted
• An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance TherapyCompletedNCT01416610Results posted
• The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis PatientsCompletedNCT01413360Phase 4Results posted
• Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)CompletedNCT01405937Phase 3Results posted
• Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)CompletedNCT01405560Phase 3Results posted
• Impact of Physician Directed Education on Patient Compliance With Hepatitis C TherapyCompletedNCT01405027Phase 4Results posted
• Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedNCT01399619Phase 3Results posted
• A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)CompletedNCT01396005Phase 1Results posted
• An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and RibavirinCompletedNCT01392742Results posted
• Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)CompletedNCT01390844Phase 3Results posted
• Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)CompletedNCT01390428Phase 1Results posted
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCompletedNCT01389323Phase 3Results posted
• 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)CompletedNCT01378104Phase 4Results posted
• Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)CompletedNCT01370642Phase 3Results posted
• A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01366638Phase 3Results posted
• A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3CompletedNCT01364090Phase 4Results posted
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCompletedNCT01359644Phase 2Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedNCT01358864Phase 3Results posted
• Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501CompletedNCT01355289Phase 2Results posted
• 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus InfectionCompletedNCT01349465Phase 3Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedNCT01343888Phase 3Results posted
• Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)TerminatedNCT01340573Results posted
• The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected PatientsCompletedNCT01335230Results posted
• A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
• Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6CompletedNCT01329978Phase 2Results posted
• A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis BCompletedNCT01327547Phase 4Results posted
• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve ParticipantsCompletedNCT01318694Phase 3Results posted
• Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected SubjectsCompletedNCT01314261Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT01306617Phase 2Results posted
• Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
• A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsCompletedNCT01292239Phase 3Results posted
• A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based TherapyCompletedNCT01290731Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected ParticipantsCompletedNCT01290679Phase 3Results posted
• An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected PatientsCompletedNCT01289782Phase 3Results posted
• A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based TherapyCompletedNCT01288209Phase 3Results posted
• Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV MedsCompletedNCT01285050Phase 4Results posted
• An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous TherapyCompletedNCT01281839Phase 3Results posted

← Hepatitis C overview